Arbutus Biopharma Corp (ABUS) Expected to Post Earnings of -$0.46 Per Share

Share on StockTwits

Equities analysts forecast that Arbutus Biopharma Corp (NASDAQ:ABUS) will announce earnings per share (EPS) of ($0.46) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Arbutus Biopharma’s earnings, with estimates ranging from ($0.57) to ($0.37). Arbutus Biopharma reported earnings of ($0.90) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 48.9%. The firm is scheduled to announce its next earnings report on Wednesday, March 13th.

According to Zacks, analysts expect that Arbutus Biopharma will report full year earnings of ($1.18) per share for the current year, with EPS estimates ranging from ($1.24) to ($1.09). For the next year, analysts forecast that the firm will report earnings of ($1.58) per share, with EPS estimates ranging from ($1.80) to ($1.35). Zacks’ earnings per share averages are a mean average based on a survey of analysts that cover Arbutus Biopharma.

Arbutus Biopharma (NASDAQ:ABUS) last released its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.13). The company had revenue of $1.59 million for the quarter, compared to analysts’ expectations of $0.23 million. Arbutus Biopharma had a negative return on equity of 75.07% and a negative net margin of 515.00%.

ABUS has been the subject of several research reports. ValuEngine cut shares of Arbutus Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 9th. Zacks Investment Research cut shares of Arbutus Biopharma from a “buy” rating to a “hold” rating in a research note on Tuesday, July 24th. JMP Securities cut shares of Arbutus Biopharma to a “market perform” rating in a research note on Tuesday, October 9th. Chardan Capital restated a “buy” rating and set a $11.00 price objective on shares of Arbutus Biopharma in a research note on Monday, July 16th. Finally, BidaskClub cut shares of Arbutus Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $7.63.

In other Arbutus Biopharma news, insider Michael J. Sofia sold 4,250 shares of Arbutus Biopharma stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $9.51, for a total transaction of $40,417.50. Following the completion of the sale, the insider now directly owns 1,499,153 shares in the company, valued at approximately $14,256,945.03. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 7.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. RTW Investments LP lifted its stake in Arbutus Biopharma by 0.3% during the 2nd quarter. RTW Investments LP now owns 5,165,499 shares of the biopharmaceutical company’s stock valued at $37,708,000 after acquiring an additional 13,884 shares during the period. BlackRock Inc. lifted its stake in shares of Arbutus Biopharma by 246.6% in the 2nd quarter. BlackRock Inc. now owns 2,391,143 shares of the biopharmaceutical company’s stock valued at $17,455,000 after purchasing an additional 1,701,237 shares during the period. Bank of Montreal Can acquired a new position in shares of Arbutus Biopharma in the 2nd quarter valued at $6,897,000. EAM Investors LLC acquired a new position in shares of Arbutus Biopharma in the 3rd quarter valued at $3,241,000. Finally, Northern Trust Corp acquired a new position in shares of Arbutus Biopharma in the 2nd quarter valued at $2,164,000. Institutional investors and hedge funds own 39.98% of the company’s stock.

Shares of NASDAQ ABUS opened at $5.40 on Friday. The company has a quick ratio of 13.67, a current ratio of 13.67 and a debt-to-equity ratio of 0.01. Arbutus Biopharma has a 12 month low of $4.01 and a 12 month high of $12.60. The company has a market cap of $263.17 million, a price-to-earnings ratio of -3.02 and a beta of 1.59.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi).

Further Reading: What is a Swap?

Get a free copy of the Zacks research report on Arbutus Biopharma (ABUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply